Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 3/20 | 0.52 |
| ▸ | CTSV | O60911 | 2/20 | 0.52 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.47 |
| ▸ | XDH | P47989 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2063188 | 0.93 | CTSV (0.60) | IMPDH2CTSLCTSVSRD5A1SRD5A2 | |
| SCHEMBL5254479 | 0.85 | CCNT1 (0.42) | IMPDH2POLBALDH1A1MAPTHPGD | |
| SCHEMBL187603 | 0.83 | IMPDH2 (0.62) | IMPDH2CTSLCTSVSRD5A1SRD5A2 | |
| SCHEMBL5255220 | 0.82 | KDM4E (0.37) | KDM4ESRC | |
| SCHEMBL5254593 | 0.82 | KDM4E (0.37) | KDM4ESRC | |
| SCHEMBL6184634 | 0.81 | IMPDH2 (0.56) | IMPDH2CTSLCTSVXDHALDH1A1 | |
| SCHEMBL4985931 | 0.78 | PRKAB2 (0.41) | POLBALDH1A1MAPTHPGDKDM4E | |
| SCHEMBL13915677 | 0.77 | POLB (0.47) | IMPDH2CTSLCTSVPOLBALDH1A1 | |
| SCHEMBL4765036 | 0.77 | KDM4E (0.47) | IMPDH2XDHPOLBALDH1A1MAPT | |
| SCHEMBL6382982 | 0.76 | KDM4E (0.44) | CTSLCTSVPOLBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171874-A1 | METHOD FOR THE REGIOSELECTIVE PREPARATION OF SUBSTITUTED BENZO[G]QUINOLINE-3-CARBONITRILES AND BENZO[G]QUINAZOLINES | WYETH (US) | 2008-07-17 | — | — | US | disclosed |
| US-7365197-B2 | Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines | WYETH (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1242382-B1 | TRICYCLIC PROTEIN KINASE INHIBITORS | WYETH CORP (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20060247217-A1 | Tricyclic protein kinase inhibitors | BERGER DAN M | 2006-11-02 | — | — | US | disclosed |
| US-7105531-B2 | Tricyclic protein kinase inhibitors | WYETH (US) | 2006-09-12 | — | — | US | disclosed |
| US-20060041127-A1 | Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines | WYETH | 2006-02-23 | — | — | US | disclosed |
| US-20040110762-A1 | Tricyclic protein kinase inhibitors | WYETH | 2004-06-10 | — | — | US | disclosed |
| US-6638929-B2 | Compounds containing nicotinonitrile rings; anticarcinogenic and -tumor agents; polycystic kidney disease and colonic polyps; antiproliferative agents; angiogenesis inhibitors; restenosis; atherosclerosis; angiofibromas; hemangiomas; | WYETH | 2003-10-28 | — | — | US | disclosed |
| EP-1345889-A1 | METHOD FOR THE REGIOSELECTIVE PREPARATION OF SUBSTITUTED BENZO G]QUINOLINE-3-CARBONITRILES AND BENZO G]QUINAZOLINES | Wyeth (US) | 2003-09-24 | — | — | EP | disclosed |
| EP-1242382-A1 | TRICYCLIC PROTEIN KINASE INHIBITORS | Wyeth (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020091273-A1 | Method for the regioselective preparation of substituted benzo[g]quinoline3-carbonitriles and benzo[g]quinazolines | AMERICAN HOME PRODUCTS CORPORATION | 2002-07-11 | — | — | US | disclosed |
| WO-2002053528-A1 | METHOD FOR THE REGIOSELECTIVE PREPARATION OF SUBSTITUTED BENZO[G]QUINOLINE-3-CARBONITRILES AND BENZO[G]QUINAZOLINES | WYETH (US) | 2002-07-11 | — | — | WO | disclosed |
| US-20010051620-A1 | Tricyclic protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-12-13 | — | — | US | disclosed |
| WO-2001047892-A1 | TRICYCLIC PROTEIN KINASE INHIBITORS | WYETH (US) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110762-A1 | Tricyclic protein kinase inhibitors | CDK1, CDKN1A, CDK2 | IMPDH2 1809/4885CTSL 2661/4885CTSV 2652/4885 |
| US-20080171874-A1 | METHOD FOR THE REGIOSELECTIVE PREPARATION OF SUBSTITUTED BENZO[G]QUINOLINE-3-CARBONITRILES AND BENZO[G]QUINAZOLINES | PDXK, PKD1, GLS | IMPDH2 3451/4885CTSL 1738/4885CTSV 1093/4885 |
| US-20060247217-A1 | Tricyclic protein kinase inhibitors | CDK1, CDKN1A, CDK2 | IMPDH2 1643/4885CTSL 2555/4885CTSV 2553/4885 |
| US-20010051620-A1 | Tricyclic protein kinase inhibitors | CDK1, CHEK1, ABL1 | IMPDH2 2193/4885CTSL 2868/4885CTSV 3757/4885 |
| US-20060041127-A1 | Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines | PDXK, PKD1, GLS | IMPDH2 3451/4885CTSL 1738/4885CTSV 1093/4885 |
| US-20020091273-A1 | Method for the regioselective preparation of substituted benzo[g]quinoline3-carbonitriles and benzo[g]quinazolines | PDXK, PKD1, PFKP | IMPDH2 3568/4885CTSL 2043/4885CTSV 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.